Kornimate/medical-research-clean huggingface dataset:
evaluation of platelet rich plasma in skin graft take for patients with post burn raw areas

Conditions: Skin Burn

Summary: 1. to evaluate the effect of the platelet rich plasma on the take of split thickness skin graft and its early and late results in resurfacing of post burn raw areas. 2. to evaluate the effect of prp on wound healing on skin graft donor site.

burn injuries involve tissue destruction due to energy transfer,the burn injuries can be caused by heat from hot liquids, solids or fire, an less common causes are friction, heat, chemical or electric sources the treatment of burns is complex due to the combination of hypermetabolic physiological response and the need for good functional and cosmetic recovery. split thickness skin grafts (stsgs) are commonly used to resurface large areas of post burn raw areas. the time to complete wound healing ranged from 2 to 75 days. factors that significantly affected time to complete wound healing were graft loss by seroma, presence of hypergranulation tissue, premorbid conditions, and total body surface area burned. generally, skin graft undertakes three steps for healing: anchorage, inosculation, and maturation. haematoma, shearing, and infection on recipient sites of skin graft can reduce skin graft take, and even lead to skin graft loss. platelet-rich plasma (prp) is an autologous blood-derived biomaterial that is enriched with a 2- to 6-fold concentration of platelets in comparison to normal human platelet concentration. multiple growth factors and bioactive proteins are stored in α-granules of platelets. these growth factors can promote proliferation of endothelial cells, epithelial cells as well as fibroblasts, and increase angiogenesis. the potential clinical application of prp in skin graft might rely on its haemostasis, adhesive, antibacterial and healing properties.

Eligibility criteria:
inclusion criteria: 1. age (15- 60 years). 2. post burn raw area less than 10 % of total body surface area . 3. selected donor sites. exclusion criteria: 1. raw area due to other causes ( trauma, ischemia,..etc) 2. patients with bleeding tendency. 3. patients with comorbidities(diabetes, malignancy,..etc)
acceptance and commitment therapy for insomnia

Conditions: Insomnia

Summary: insomnia is a frequent complaint and is associated with impairments in physical and psychological health. although cognitive-behavioral therapy (cbt) demonstrates effective results for insomnia, there are those who do not respond to this type of intervention or present difficulties in adherence. acceptance and commitment therapy (act) presents itself as a potentially useful intervention for the treatment of insomnia, for which, instead of focusing on controlling the symptoms, the respective approach focuses on accepting the feelings and thoughts associated, through value-based actions. the aim of this study is to evaluate the effectiveness of act for chronic insomnia in adults. participants will be 150 adults aged between 18 and 59 years, diagnosed with chronic insomnia who will be randomly assigned to the act, cbt and wait list (wl) groups. for both groups (act and cbt), the intervention will be performed in six group and weekly sessions. assessments of sleep patterns, insomnia, depression, anxiety, psychological flexibility, acceptance of sleep, beliefs about sleep, personality traits will be performed in the pre-treatment, post-treatment and six-month follow-up. after the intervention is completed, participants will respond to an inventory of compliance and satisfaction. treatment effects will assessed using the fixed effects of group variables (act vs. cbt-i and act vs. waitlist) and their interaction with time (pre-test vs. post-test and pretest vs. six-month follow-up). estimated pairwise contrasts to examine changes across time within groups will be used. variables will analyzed using generalized mixed models (gmm).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic insomnia exclusion criteria: * neurological degenerative disease * psychotic disorder * sleep apnea, restless legs or periodic limb movements during sleep, or a circadian-based sleep disorder (e.g., delayed or advanced sleep phase syndrome) * cognitive impairments * unavailability in attending the sessions.

Keywords: insomnia acceptance and commitment therapy cognitive behavioral therapy sleep
hepat1ca: quantifying liver health in surgical candidates for liver malignancies

Conditions: Liver Cancer; Surgery; Liver Regeneration; Colorectal Cancer Metastatic

Summary: this observational clinical cohort study aims to evaluate the clinical utility of livermultiscan in quantifying liver health prior to liver resection or tace. the results will enable further developments in scanning protocols and software, and clearly define the relevance of applying this technology as part of the pre-operative assessment of the patient being considered for liver resection or tace.

the liver is unique among the abdominal organs for the capacity to regenerate post-operatively. however, a minimum functional liver remnant (flr) is required for patients to survive the initial perioperative period. at present, the assessment of the flr is based on volume alone, in the context of clinical judgment and surrogate markers of liver function based on blood tests. recently, perspectum diagnostics have developed and validated livermultiscan, an mri-based technology that can non-invasively quantify fibroinflammatory disease in addition to steatosis and iron content. in this project, we plan to use livermultiscan as an additional direct measurement of liver health prior to resectional surgery or transarterial chemoembolization (tace), so that liver volume and function can be combined. for example, surgery with a predicted flr of 21% might be survivable if the liver tissue was in extremely good health, whereas surgery with a predicted flr of 40% might be lethal if the liver tissue was in poor health. occasionally, portal vein embolization (pve) is performed to promote hypertrophy of the flr. furthermore, non-resectional intervention, for example tace for primary liver cancers, is well-tolerated by patients with healthy livers, but can lead to serious liver decompensation and liver failure if tace is delivered to a liver in poor health. currently, the available imaging modalities are limited in their ability to assess liver health in liver resection or tace candidates. liver fat content (steatosis) can be assessed with ct, or more accurately with mri. however, fibroinflammatory disease, which has been shown to correlate with post-resection morbidity, typically requires an invasive biopsy to diagnose accurately. this research project will support the definition, development and technical validation of hepatica, which aims to build on the mri technology underlying livermultiscan and develop the additional functionality required to meet this clinical need.

Eligibility criteria:
inclusion criteria: * patients being considered for liver resection exclusion criteria: * i. patients under the age of 18 years will be excluded from the present study. ii. prisoners will be excluded from the present study. iii. persons unable to have an mri scan (including but not limited to claustrophobia, implanted metallic devices, metal foreign body) iv. adults with incapacity v. non-provision of consent

Keywords: livermultiscan multiparameter mri functional liver remnant liver resection hepatic resection portal vein embolisation preoperative liver function postoperative liver failure
rollover study for continuing valbenazine (nbi-98854) administration for the treatment of tardive dyskinesia

Conditions: Tardive Dyskinesia

Summary: this phase 3b, rollover study will provide participants who completed a phase 3 valbenazine (nbi-98854) study open-label access to valbenazine (fixed doses administered once daily) for the treatment of adults with td until valbenazine is anticipated to be available commercially or they complete 72 weeks of treatment. this study will allow enrollment of up to 150 medically stable male and female participants with td who previously participated in and completed the nbi-98854-1304 (kinect 3) or nbi-98854-1402 (kinect 4) phase 3 study.

this study was terminated after 60 weeks due to the commercial availability of valbenazine.

Eligibility criteria:
inclusion criteria: * have participated in and completed the nbi-98854-1304 (kinect 3) or nbi-98854-1402 (kinect 4) phase 3 study. * participants of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently throughout the study and until 30 days after the last dose of valbenazine. * if using maintenance medication(s) for schizophrenia or schizoaffective disorder, mood disorder, or other conditions, be on stable doses. * be in general good health. * have adequate hearing, vision, and language skills to perform the procedures specified in the protocol. exclusion criteria: * have an active, clinically significant unstable medical condition within 1 month prior to screening. * have a known history of substance dependence, substance (drug) or alcohol abuse. * have a significant risk of suicidal or violent behavior. * have a known history of neuroleptic malignant syndrome. * have a known history of long qt syndrome or cardiac arrhythmia. * have a cancer diagnosis within 3 years prior to screening (some exceptions allowed). * have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than valbenazine) during the study. * have a blood loss ≥550 ml or donated blood within 30 days prior to baseline. * have an allergy, hypersensitivity, or intolerance to tetrabenazine. * are currently pregnant or breastfeeding.
interaction of potassium and genetic risk variants on diabetes risk

Conditions: Diabetes

Summary: the investigators propose to study the association of the kcnj11 (potassium voltage-gated channel subfamily j member 11) polymorphisms on diabetes risk in the atherosclerosis risk in communities (aric) and jackson heart study (jhs) cohorts. the investigators also propose to test for an interaction between serum k and these genetic variants. by testing for such an interaction, it will be determined if, among participants with these genetic variants, a low-normal serum k was a stronger predictor of diabetes risk compared to those participants without these genetic variants.


Eligibility criteria:
inclusion criteria: * member of the atherosclerosis risk in communities (aric) study or jackson heart study (jhs) cohorts exclusion criteria: * had not fasted 8 or more hours for the baseline visit * prevalent diabetes at baseline exam * missing information on serum potassium * missing single nucleotide polymorphism (snp) data * evidence of kidney dysfunction * race other than black/african american or white/caucasian * missing other covariates

Keywords: potassium genetic variants
inturlekin l33 in ankylosing spondylities patients and its relation to subclinical atherosclerosis

Conditions: Ankylosing Spondylitis

Summary: detect level of inturlekin 33 in ankylosing spondyilits patient measure cimt (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients detect the relation between il33 and subclinical atherosclerosis in ankylosinig spondylitis patients

ankylosing spondylitis (as), a type of spa, is an autoimmune disease that mainly involves, sacroiliac joints (sijs) and their adjacent soft tissues, such as tendons and ligaments. the main clinical manifestations include back pain and progressive spinal rigidity as well as inflammation of the hips, shoulders, peripheral joints and fingers/toes. in addition, there are extra-articular manifestations. cardiovascular disease has become the first cause of death for patients with ankylosing spondylitis (as). patients with ankylosing spondylitis (as) have an increased cardiovascular morbidity and mortality . accelerated atherosclerosis caused by a systemic inflammatory response has been reported to be an important risk factor for increased cardiovascular risk for autoimmune diseases. interleukin (il)-33 is a cytokine belonging to the il-1 family and was recently identified as a ligand for st2, .the serum levels of il-33/sst2 were remarkably higher in the patients with as than the healthy groups . pervious studies confirm the importance of il-33/st2 axis in the process of atherosclerosis, and indicate its ambiguous function in immune response, whether as proinflammatory cytokine in advanced atherosclerotic lesions, or as profibrotic, in early lesions. previous study shows increased cimt in as patients without traditional cardiovascular risk factors compared to healthy controls.

Eligibility criteria:
inclusion criteria: * patient diagnosed as ankylosing spondylitis * age (20-40) exclusion criteria: * patients with other rheumatic diseases/other spa types * participants with history of cvd event in past or present * patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months. * patient with other risk factor for atherosclerosis.
degenerative nigrostriatal dysfunction in drug-induced parkinsonism

Conditions: Secondary Parkinsonism; Parkinson's Disease

Summary: parkinson's disease (pd) and drug-induced parkinsonism (dip) can be clinically indistinguishable and dip sometimes represents "unmasking of underlying pd. the objective of this study is to determine the relationship of underlying parkinson's disease (pd) to the incidence and clinical outcome in dip using non-motor assessments as a marker for nigrostriatal degeneration. research design: this is a nested case-control design to investigate risk factors associated with the development of dip and persistent parkinsonism after antipsychotic (ap) withdrawal (a potential clinical marker of underlying pd). target enrollment is 45 subjects. methodology: we will examine objective olfactory function (via objective olfactory testing), other non-motor symptoms of pd (via standardized validated questionnaires), and motor findings (via clinical exam and quantitative gait analysis) in: 1) dip patients (30 subjects) compared to ap-treated patients without parkinsonism (15 subjects) and 2) patients with persistent parkinsonism compared to those whose symptoms resolve in the dip cohort followed prospectively after a change in ap treatment. additionally, in patients where it was performed clinically, we will evaluate dopamine transporter spect imaging (dati) as a marker of nigrostriatal integrity examining the ability of qualitative and semi-quantitative analysis to distinguish between pharmacologic and degenerative parkinsonism. we will also measure serum uric acid and apolipoprotein a1, two putative biomarkers in early pd, and examine their relationship with clinical and radiologic status.


Eligibility criteria:
inclusion criteria: antipsychotic treated patients with or without parkinsonism exclusion criteria: parkinson's disease, dementia
investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (ra) patients who had an inadequate response to mtx therapy

Conditions: Arthritis, Rheumatoid

Summary: this is a phase iii, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week open-label period. the primary purpose of the study is to demonstrate the efficacy of ofatumumab in reducing clinical signs and symptoms in adult ra patients after a single course of ofatumumab.

this study consists of a double-blind , placebo controlled, and parallel group part with eligible patients enrolled into a 24 week double-blind period, and randomized in a 1:1 ratio to receive ofatumumab (700mg x 2 infusions) or placebo ( saline x 2 infusions) in addition to their background methotrexate treatment. patients who completed the 24 week double-blind period without receiving rescue dmard treatment will be eligible to proceed into the 120 week open-label period to receive repeat treatment courses with ofatumumab. in the open-label period ofatumumab treatment courses will be given at individualized time intervals only if a clinical response has been achieved following the previous treatment course, and followed by a subsequent worsening in disease activity . patients who have completed the open-label period or have withdrawn will enter a maximum 2 year follow-up period, or until their bcells return to normal or to baseline levels, whichever occurs earlier.

Eligibility criteria:
inclusion criteria * age ≥ 18 years; * active disease at the time of screening as defined by: ≥ 8 swollen joints (of 66 joints assessed) and ≥ 8 tender joints (of 68 joints assessed), c-reactive protein (crp) ≥ 1.0 mg/dl or erythrocyte sedimentation rate (esr) ≥ 22 mm/hour, das28≥3.2 (based on esr); * inadequate response to previous or current methotrexate treatment; * treatment with methotrexate (mtx), 7.5-25 mg/week, for at least 12 weeks and at a stable dose for at least 4 weeks. exclusion criteria * patients with a history of a rheumatic autoimmune disease other than ra or with significant systemic involvement secondary to ra; * previous exposure to biologic anti-rheumatic therapies, including investigational compounds; * previous exposure to biologic dmards; chronic or ongoing active infectious disease requiring systemic treatment; * clinically significant cardiac disease; history of significant cerebrovascular disease; * significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease, or evidence of demyelinating disease; * known hiv positive; serologic evidence of hepatitis b infection; positive test for hepatitis c; positive plasma / white cell jc virus pcr; * serum igg \< lower limit of normal; * breast feeding women or women with a positive pregnancy test at screening; * current participation in any other interventional clinical study; * patients known or suspected of not being able to comply with a study protocol.
a study of denufosol tetrasodium intravitreal injection in subjects with post cataract extraction macular edema

Conditions: Macular Edema, Cystoid

Summary: the purpose of this study is to investigate the safety and tolerability of three dose strengths of the study drug in subjects with post cataract extraction macular edema.


Eligibility criteria:
inclusion criteria: * have persistent post cataract extraction macular edema whose condition is stable * have no change in medication regimen of immunosuppressive or anti-inflammatory agents; steroidal or non-steroidal agents for a specified period of time prior to randomization * have at least one eligible eye to be treated in the study * have an optical coherence tomography (oct) scan with a qualifying retinal thickness in the study eye * have macular edema confirmed by fluorescein angiography exclusion criteria: * have proliferative vitreoretinopathy greater than grade b in either eye * have ocular disorders in the study eye that may confound interpretation of study results * have ophthalmic disorders in the study eye that may influence final visual acuity and/or fluorescein angiography interpretation * have had cataract surgery in the study eye in the past 2 months, yag laser capsulotomy within the past 1 month, or any other intraocular surgery within the past 90 days * have uncontrollable elevated intraocular pressure (iop) or advanced glaucoma * have had any periocular or intravitreal injection of corticosteroids in the study eye within 3 months * have had any ocular implant device for the delivery of therapeutic agents * be taking any excluded medications that could obscure or confound study results

Keywords: macular edema post cataract extraction cystoid macular edema post cataract extraction macular edema
mindfulness and intercare based intervention for medicine students (miim)

Conditions: Depressive Symptoms; Mental Health Wellness 1; Anxiety

Summary: the effects of coronavirus disease (covid-19) pandemic on health, economy and social network has an impact on mental health, specially students. the aim of the study was to evaluate the effectiveness of a brief online mindfulness, compassion and intercare based intervention in medicine students in santiago de chile. randomized controlled trial was conducted. enrolled participants were randomly assigned to 1) a mindfulness, compassion and intercare based intervention, 2) a psychoeducational intervention or 3) waiting list. both intervention lasted 1 hour per week for 4 weeks. academic flexibility, breaks and individual psychological help was offered to the whole group. an online assessment of well being, anxiety and depression symptoms was completed at the beginning, 1 month and 3 month.


Eligibility criteria:
inclusion criteria: * medicine students * 1st to 7th class year exclusion criteria: * recent grief * severe acute depression disorder * active suicidal ideation * active psychosis * active addiction * post traumatic stres disorder
follicular flushing outcomes in singles versus double lumen oocyte retrieval needles in poor responding patients

Conditions: Infertility

Summary: in this study, the investigators aimed to evaluate to the efficacy of the needle type used in follicular flushing in oocyte retrieval in the poorest responders undergoing ivf.

this study will include: 1. women with less than four follicles on the day of hcg administration 2. women between 20-45 age old 3. the value of progesterone on the day of hcg administration will be under 1.5ng/ml

Eligibility criteria:
inclusion criteria: 1. women between 20-45 years old 2. the number of follicles less than 5 on the day of hcg administration 3. the value of progesteron on the day of hcg administration must be under 1.5ng/ml exclusion criteria: 1. women under 20 years and older than 45 year 2. on the day of hcg administration if the follicle number is more than 5 3. if.the value of progesteron on the day of hcg administration is higher than 1.5ng/ml

Keywords: follicular flushing ivf poor responders oocyte retrival
radiotherapy in association with cetuximab in patients treated for an epidermoid cancer

Conditions: Epidermoid Head and Neck Cancer

Summary: this study evaluates the skin toxicities in patients with epidermoid cancer, treated by radiotherapy in association with cetuximab.


Eligibility criteria:
inclusion criteria: * age \> 18 years * epidermoid head and neck carcinoma locally advanced * indication of cetuximab and radiotherapy * karnofsky \>= 60 * patients participating to another compatible study could be included after consultation with the study director patients could be beforehand treated for an other orl cancer the radiotherapy will be delivered for curative aim (minimal dose 66 gy) exclusion criteria: * other histology * metastatic disease * recurrent patients

Keywords: cetuximab radiotherapy epidermoid head and neck cancer
association with spinal needle-puncture pain and menstrual phase

Conditions: Pain

Summary: this prospective observational study aimed to evaluate the relationship between menstrual phase cycles and spinal needle-puncture pain during spinal anesthesia in female patients of reproductive age.

before the spinal anesthesia procedure, the anxiety and depression levels of the patients will be evaluated with the 14-scale 'hospital anxiety and depression scale.' the spinal anesthesia procedure will be performed by the anesthesiologist responsible for the patient. at the end of the spinal anesthesia procedure, a researcher with no knowledge of the patient's menstrual phase information will ask rate the spinal needle-puncture pain felt during spinal anesthesia with a numerical rating scale (nrs), which is graded from 1 to 10 (0: no pain, 10: very severe pain).

Eligibility criteria:
inclusion criteria: * female volunteers of reproductive age have had a regular menstrual cycle for at least six months exclusion criteria: * pregnancy * asa physical status iii and iv * patients with psychiatric disorders, * emergency surgeries * mentally retarded patients, * patients with multiple spinal anesthesia trials * patients with previous spinal surgery experience